Clinical and Pharmacological Relevance
Start with the big picture
Biotransformation generally makes lipophilic xenobiotics more hydrophilic so they can be excreted. Phase I reactions—oxidation, reduction, and hydrolysis—introduce or expose functional groups; Phase II adds conjugates, and Phase III transporters help move conjugates toward elimination. These processes have practical consequences: CYP enzyme induction can lower concentrations of some drugs, while inhibition can raise them and increase toxicity risk. The lesson also connects metabolism to acetaminophen toxicity and glutathione, smoking-related CYP1A2 induction, ethanol’s effects on CYP2E1, and reduced metabolic capacity in some age and disease contexts. Together, these examples show why biotransformation is central to medication response and safety.
What you'll learn
- Distinguish the roles of Phase I, Phase II, and Phase III biotransformation.
- Relate CYP induction and inhibition to changes in drug levels and clinical effects.
- Explain how acetaminophen metabolism and glutathione relate to hepatotoxicity.
- Identify how smoking, ethanol, age, disease, and nutrition can affect drug metabolism.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
